India Can Emerge as a Hub for Rare Disease Medicines

UPDATE - follow-up to Why rare-disease drugs could become India's next pharma frontier: India holds immense potential to become a global hub for rare-disease pharmaceuticals by combining its large patient population, established manufacturing strengths, and structured clinical trial partnerships.

Market Scale and Challenges

Each rare disease affects very few people, but roughly 8,000 such conditions cumulatively impact hundreds of millions worldwide, with 1,004 rare genetic disorders reported in India so far. Historically called orphan drugs due to limited commercial interest, these treatments often cost $100,000 or about Rs 1 crore per year. While the Indian government provides up to Rs 50 lakh for patient treatment, this often falls short, leading families to rely on platforms where nearly 4,000 children are listed with a cumulative annual treatment cost exceeding Rs 9,000 crore.

Clinical Trials and Global Race

India's population of over 1.4 billion and high endogamy in certain social groups create concentrated patient cohorts, such as a 10.5% beta-thalassemia prevalence in specific ethnic groups compared to 3.7% generally. Patient advocacy groups are increasingly organized, with some tracking cohorts like 70 people with GNE myopathy or over 400 Rett syndrome patients in a registry. As U.S. and Chinese companies race to develop rare-disease drugs, foreign firms could collaborate with India for clinical trials and manufacturing, much like the chip manufacturing sector.

Regulatory Pathways

India already supplies 47% of generic prescriptions in the U.S. and maintains the largest number of U.S.-regulated manufacturing sites outside America. Under Rule 101 of the New Drugs and Clinical Trials Rules 2019, the Central Drugs Standard Control Organisation allows drugs approved in six specific countries like the U.S. and U.K. to skip new local clinical trials before seeking approval, provided there are proper checks for bioequivalence, safety, and quality.

Context

India has long earned the title of the pharmacy of the world by supplying affordable generic medicines and biosimilars globally. Expanding this capability into rare diseases relies on pairing international drug research with India's low-cost manufacturing capacity and large patient pools.